Drug-resistant MS spasticity treatment with Sativex® add-on and driving ability

Acta Neurologica Scandinavica

Volumn 131, Issue 1, 2016, Pages 9-16

  Freidel, M ^a   Tiel Wilck, K ^b   Schreiber, H ^c   Prechtl, A ^d   Essner, U ^e   Lang, M ^c  

^a NeuroPraxis MS Zentrum   (Germany)

^b NeuroTransData GmbH   (Germany)

^c NTD Study Group   (Germany)

^d Almirall Hermal   (Germany)

^e O MEANY Consultancy GmbH   (Germany)

Author keywords

Computerized test battery; Driving ability; MS spasticity; Tetrahydrocannabinol cannabidiol

Indexed keywords

NABIXIMOLS; PLANT EXTRACT; TETRAHYDROCANNABINOL-CANNABIDIOL COMBINATION;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DIZZINESS; DRIVING ABILITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; ORAL SPRAY; SPASTICITY; SPRAIN; THROMBOSIS; TREATMENT OUTCOME; VERTIGO; CAR DRIVING; COMPLICATION; GERMANY; MIDDLE AGED; MUSCLE SPASTICITY; PILOT STUDY;

ADULT; AUTOMOBILE DRIVING; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PILOT PROJECTS; PLANT EXTRACTS;

EID: 84919959419     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12287     Document Type: Article

References (31)

1. Pugliatti M, Rosati G, Carton H et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006;13:700-22.
2. Kister I, Bacon TE, Chamot E et al. Natural history of multiple sclerosis symptoms. Int J MS Care 2013;15:146-58.
3. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004;10:589-95.
4. Oreja-Guevara C. Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids. Rev Neurol 2012;55:421-30.
5. Flachenecker P, Henze T, Zettl UK. Spasticity in patients with multiple sclerosis-clinical characteristics, treatment and quality of life. Acta Neurol Scand 2014;129:154-62.
6. Diener H. Leitlinien für Diagnostik und Therapie in der Neurologie, 5th edn. Stuttgart: Thieme, 2012.
7. Collin C, Davies P, Mutiboko IK, Ratcliff S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290-6.
8. ®, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;32:451-9.
9. ®®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18:1122-31.
10. Wade DT, Makela PM, House H, Batman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12:639-45.
11. ®®) in people with multiple sclerosis: a new approach. Trials 2012;13:189.
12. ®(R) (nabiximols). Mult Scler 2012;18:219-28.
13. ® long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 2013;260:285-95.
14. Fernandez O, Arnal-Garcia C, Arroyo-Gonzalez R et al. Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II). Rev Neurol 2013;57:269-81.
15. Wang T, Collet J, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ 2008;178:1669-78.
16. Leussink VI, Husseini L, Warnke C, Broussalis E, Hartung HP, Kieseier BC. Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. Ther Adv Neurol Disord 2012;5:255-66.
17. ®. Results from clinical practice. Mult Scler 2013;19:(S1)P1041.
18. ® (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010;16:707-14.
19. Garcia-Merino A. Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert Rev Neurother 2013;13(3 Suppl 1):9-13.
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
21. Farrar JT, Troxel AB, Stott C, Dunconmbe B, Jensen MP. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008;30:974-85. http://www.sciencedirect.com/science/article/pii/S0149291808001811.
22. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-5.
23. Gräcmann N, Albrecht M. (Stand 2. November 2009): Begutachtungs-Leitlinien zur Kraftfahrereignung Bundesanstalt für Straβenwesen, Bergisch Gladbach, Dezember 2010.
24. Schuhfried GmbH. Wiener Testsystem, Manual FEV Anlage 5 Nr.2. Mödling, Austria, 2012.
25. Wong SL, Sharrack B. A survey of advice on driving in neurological conditions amongst neurologists and neurosurgeons. J Neurol Neurosurg Psychiatry 2013;84:e2.
26. Devos H, Brijs T, Alders G, Wets G, Feys P. Driving performance in persons with mild to moderate symptoms of multiple sclerosis. Disabil Rehabil 2013;35:1387-93.
27. Marcotte TD, Rosenthal TJ, Roberts E et al. The contribution of cognition and spasticity to driving performance in multiple sclerosis. Arch Phys Med Rehabil 2008;89:1753-8.
28. Akinwuntan AE, Devos H, Stepleman L et al. Predictors of driving in individuals with relapsing-remitting multiple sclerosis. Mult Scler 2013;19:344-50.
29. Lincoln NB, Radford KA. Cognitive abilities as predictors of safety to drive in people with multiple sclerosis. Mult Scler 2008;14:123-8.
30. Schultheis MT, Weisser V, Ang J et al. Examining the relationship between cognition and driving performance in multiple sclerosis. Arch Phys Med Rehabil 2010;91:465-73.
31. ®) in the management of spasticity associated with multiple sclerosis. Expert Rev Neurother 2011;11:627-37.